SMS Lifesciences zooms on getting EIR from USFDA for API manufacturing facility in Telangana
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
SMS Lifesciences India is currently trading at Rs. 683.85, up by 30.05 points or 4.60% from its previous closing of Rs. 653.80 on the BSE.
The scrip opened at Rs. 667.50 and has touched a high and low of Rs. 700.00 and Rs. 659.85 respectively.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1022.50 on 28-Oct-2021 and a 52 week low of Rs. 560.00 on 26-May-2022.
Last one week high and low of the scrip stood at Rs. 700.00 and Rs. 652.80 respectively. The current market cap of the company is Rs. 211.63 crore.
The promoters holding in the company stood at 68.96%, while Non-Institutions held 31.04% stake in the company.
SMS Lifesciences India has received Establishment Inspection Report (EIR) from U.S. Food and Drug Administration (USFDA) for the inspection conducted in the month of April, 2022 at API manufacturing facility located at Kazipally, Jinnaram MandaI, Sangareddy district in Telangana. EIR from USFDA Indicates successful completion of the Inspection without any observations.
SMS Lifesciences India is presently engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of Organic & Inorganic Chemicals, Pharmaceuticals, API and Intermediates.
